Alnylam Q2 2022 Earnings Report
Key Takeaways
Alnylam Pharmaceuticals reported second quarter 2022 financial results, achieving global net product revenues of $214 million, a 33% increase compared to the same period last year. The company also received FDA approval of AMVUTTRA for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults and reiterated its 2022 financial guidance.
Achieved Second Quarter 2022 Global Net Product Revenues of $214 Million for ONPATTRO, GIVLAARI, and OXLUMO (33% Growth vs. Same Period Last Year)
Received FDA Approval of AMVUTTRA (vutrisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Expects to Report Topline Results from APOLLO-B Phase 3 Trial of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy Within the Next Three Weeks
Reiterated 2022 Financial Guidance, Including Combined Net Product Revenues of $870-$930 Million
Alnylam
Alnylam
Alnylam Revenue by Segment
Forward Guidance
Full year 2022 financial guidance is reiterated and consists of the following: Combined net product revenues for ONPATTRO, GIVLAARI, OXLUMO and AMVUTTRA $870 million - $930 million ; Net revenues from collaborations and royalties $175 million - $225 million; GAAP R&D and SG&A expenses $1,620 million - $1,700 million; Non-GAAP R&D and SG&A expenses $1,390 million - $1,450 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income